Acron Helvetia VII merges with Acron Swiss Premium Assets
Acron Helvetia VII Immobilien AG is merging with Acron Swiss Premium Assets AG. The merger was approved by an Extraordinary General Meeting.
The General Meeting resolved to dissolve the real estate fund company by merging it with Acron Swiss Premium Assets AG and approved the corresponding merger agreement.
The minority shareholders of Acron Helvetia VII Immobilien AG will receive CHF 95 in cash as compensation for one registered share with a par value of CHF 60.76. The last trading day for the shares was May 2, 2017.
Acron Swiss Premium Assets has held a majority stake in Acron Helvetia VII for almost a year. In June 2016, the company acquired Axa Leben's stake of around 59%.
The investment property is the "Portikon" office property at the Glattpark site in Zurich-Opfikon. The seven-storey, fully let property has two main tenants, Baxter Healthcare S.A. and Takeda Pharmaceuticals International GmbH. Together, the two companies have rented around 90 percent of the total space. "Portikon" is one of the largest properties in Switzerland to be designed and built to the Minergie-P standard.
